DXCM vs EMBC: fair value comparison
DexCom, Inc. and Embecta Corp. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EMBC currently sits closer to the top of our ranking by discount to fair value. DXCM carries the stronger quality grade.
| DXCM | EMBC | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $84.11 | $6.27 |
| 12-month range | $54.84–$92.34 | $2.90–$14.64 |
| Rank by discount to fair value | #13 of 108 Healthcare | #11 of 108 Healthcare |
| Quality grade | A | B |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | Strong | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: DXCM fair value analysis · EMBC fair value analysis